Lisata Therapeutics, INC. (LSTA) — 8-K Filings

All 8-K filings from Lisata Therapeutics, INC.. Browse 11 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (11)

Lisata Therapeutics Files 8-K — Oct 14, 2025 Risk: low
Lisata Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
Lisata Therapeutics Enters Material Definitive Agreement — Oct 8, 2025 Risk: medium
On October 8, 2025, Lisata Therapeutics, Inc. entered into a material definitive agreement. The company, formerly known as Caladrius Biosciences, Inc., is incor
Lisata Therapeutics Files 8-K — Jul 15, 2025 Risk: low
Lisata Therapeutics, Inc. filed an 8-K on July 15, 2025, reporting on other events and financial statements. The company, formerly known as Caladrius Bioscience
Lisata Therapeutics Files 8-K — Jun 26, 2025 Risk: low
On June 26, 2025, Lisata Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. L
8-K Filing — Jun 17, 2025
8-K Filing — Jun 13, 2025
Lisata Therapeutics Files 8-K on Shareholder Vote Matters — Jun 10, 2025 Risk: low
Lisata Therapeutics, Inc. filed an 8-K on June 10, 2025, to report on the submission of matters to a vote of security holders. The company, formerly known as Ca
LISATA THERAPEUTICS, INC. Files 8-K — Jan 23, 2025 Risk: low
On January 22, 2025, LISATA THERAPEUTICS, INC. filed an 8-K report. The filing indicates that the company's common stock is registered and traded on The Nasdaq
Lisata Therapeutics Enters Material Definitive Agreement — Dec 3, 2024 Risk: medium
On December 3, 2024, Lisata Therapeutics, Inc. (formerly Caladrius Biosciences, Inc.) entered into a Material Definitive Agreement. The company, incorporated in
Lisata Therapeutics Files 8-K on Financials — Jun 27, 2024 Risk: low
Lisata Therapeutics, Inc. filed an 8-K on June 27, 2024, to report on its results of operations and financial condition. The company, formerly known as Caladriu
Lisata Therapeutics Appoints New Director — Apr 17, 2024 Risk: low
Lisata Therapeutics, Inc. announced on April 15, 2024, a change in its Board of Directors. Specifically, Dr. Philip P. Vanek has been appointed as a new directo

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX